Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Clinical trial NCT01682213 · COMPLETED
Trial details
- NCT number
- NCT01682213
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-01
- Primary completion
- 2019-05-01
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.